Method for the diagnosis of etoposide prodrug treatable cancer
AssigneeCellAct Pharma GmbH
InventorNalan Utku
Life of this patent
Estimating the term…
Abstract
The present invention pertains to a diagnostic and therapeutic method for assessing whether a patient is susceptible to the treatment of an ester-prodrug. The methods of the invention include the analysis of carboxyelesterase 2 (CES2)-expression in tumor samples as a predictive value for the assessment of treatment success with an ester-prodrug of a chemotherapeutic agent. Alternatively, the invention provides methods involving the analysis of the urinary ratio of the prodrug and the active therapeutic as another predictive value for assessing treatment susceptibility.
Claims5
A method of stratifying and treating a patient suffering from biliary tract cancer (BTC), the method comprising the steps of
- a) providing a BTC tumor sample of the patient,
- b) determining the expression of carboxylesterase 2 (CES2) in the BTC tumor sample, wherein a lack of expression of CES2 in the BTC tumor sample indicates the risk of a patient that a treatment with an ester prodrug of a chemotherapeutic agent will not lead to a treatment success, and wherein the expression of CES2 in the BTC tumor sample indicates that a treatment with an ester prodrug of a chemotherapeutic agent will lead to a treatment success, and
- c) (i) treating the patient whose BTC tumor sample is determined to express CES2 with the ester prodrug of a chemotherapeutic, or
- (ii) treating the patient whose BTC tumor sample lacks CES2 expression with a treatment regimen that comprises a treatment that is different from the ester prodrug of a chemotherapeutic agent.
A method of assessing if a patient suffering from biliary tract cancer (BTC) is a responder to treatment with an ester prodrug of a chemotherapeutic agent and treating the patient if the patient is a responder, the method comprising the steps of
- a) providing a BTC tumor sample of the patient,
- b) determining the level of CES2 expression in the BTC tumor sample, wherein the expression of CES2 in the BTC tumor sample indicates that the patient is a responder to treatment with the ester prodrug of a chemotherapeutic agent, and wherein the lack of expression of CES2 in the BTC tumor sample indicates that the patient is a non-responder to treatment with the ester prodrug of a chemotherapeutic agent, and
- c) (i) treating the patient with the ester prodrug of a chemotherapeutic agent if the patient is a responder, or
- (ii) treating the patient with a treatment regimen that comprises a treatment that is different from the ester prodrug if the patient is a non-responder.
Dependencies are inferred from the claim text.